| Literature DB >> 25013491 |
Yiming Zhou1, Yiwen Zang1, Jianbin Xiang1, Feng Tang2, Zongyou Chen1.
Abstract
Adenoid cystic carcinoma (ACC) is a relatively common head and neck tumor, however, is rare in the digestive tracts. There have been <100 cases of esophageal ACC reported to date and no cases of gastric ACC. The present study reports the exceptional case of a 53-year-old male with a primary ACC of the cardia. The patient underwent a radical total gastrectomy with D2 lymphadenectomy and Roux-en-Y esophagojejunal reconstruction. Immunohistochemical analysis identified a case of primary ACC that exhibited a positive expression for cytokeratin, calponin, cluster of differentiation 117, p63 and smooth muscle actin, with typical cribriform foci. No signs of recurrence have been detected during the 30-month follow-up. Thus, a precise diagnosis of ACC is primarily based on the results of immunohistochemical analysis and radical resection is considered to be the best treatment option for ACC of the digestive tracts. The current study also reviewed 17 cases of ACC of the esophagus reported in China, with special reference to the criteria for histological diagnosis and therapeutic options. The prognosis of esophageal ACC is poor due to early metastasis, mainly relying on the resectability of the tumor.Entities:
Keywords: adenoid cystic carcinoma; cardia; esophagus
Year: 2014 PMID: 25013491 PMCID: PMC4081280 DOI: 10.3892/ol.2014.2153
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1Endoscopy showing a protruded lesion with shallow depressions on the surface of the cardia.
Figure 2Enhanced computed tomography scan showing the abnormally thickened stomach wall of the cardia (indicated by the star symbol). The lymph nodes around the lesser curvature were enlarged.
Figure 3Immunohistological examinations. (A) Macroscopic tumor specimen obtained from surgical resction. (B) Micrograph of the resected specimen showing a cribriform pattern in a solid nest (hematoxylin and eosin staining; magnification, ×100). (C) Immunostaining for calponin (magnification, ×40); (D) cluster of differentiation 117 (magnification, ×40); (E) p63 (magnification, ×40); and (F) smooth muscle actin (magnification, ×40).
Results of IHC of the resected tumor.
| Biomarker | IHC result |
|---|---|
| Ki-67 | 10% + |
| p53 | + |
| C-erbB-2 | c |
| Cytokeratin (AE1/AE3) | + |
| High-molecular cytokeratin | + |
| Low-molecular cytokeratin | + |
| Cytokeratin 5/6 Focal | + |
| Epithelial membrane antigen | + |
| Vimentin | + |
| p63 | + |
| Calponin | + |
| Smooth muscle actin | + |
| S-100 Focal | + |
| CD117 | + |
| CD56 | − |
| CD45/LCA | − |
| Carcinoembryonic antigen | − |
| Estrogen receptor | − |
| Progesterone receptor | − |
| Chromogranin A | − |
| Synaptophysin | − |
CD, cluster of differentiation; LCA, leukocyte common antigen; IHC, immunohistochemistry.
Clinical data of the present case and 17 other cases of ACC of the esophagus reported in China.
| Case (ref) | Age/gender | Location | Biopsy | Macroscopic appearance | Depth of invasion | Metastasis to LN | Distant metastases | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 (Present) | 53/M | Cardia | ACC | Protruding | Serosa | None | None | Surgery | Alive 30 mo. |
| 2 (6) | 47/M | Lower | SCC | Protruding | Muscule | None | None | Surgery + chemotherapy (DCVU) | NS |
| 3 (7) | 48/M | Middle | Not done | Ulcerative | Submucosa | None | None | Surgery | Alive 17 mo. |
| 4 (8) | 59/M | Middle | Focal mild hyperplasia of squamous epithelia | Protruding | Submucosa | None | None | Surgery | Alive 21 mo. |
| 5 (9) | 60/M | Lower | SCC | Protruding | Muscule | None | None | Surgery | Succumbed 22 days |
| 6 (10) | 64/F | Middle | Leiomyoma | Protruding | Muscule | None | None | Surgery | NS |
| 7–10 (11) | 42–62 (Mean, 51)/3M, 1F | 2 Middle | 1 ACC | Unknown | NS | NS | 1 Brain | 2 × surgery | NS |
| 1 Lower | 1 SCC | 2 ×biopsy | |||||||
| 1 Upper | 1 Negative | ||||||||
| 1 No biopsy | |||||||||
| 11 (12) | 60/M | Middle | SCC | Protruding | Adventitia | None | NS | Surgery | NS |
| 12 (13) | 50/M | Lower | Not done | Ulcerative | Adventitia | None | None | Surgery | Alive 30 mo. |
| 13 (14) | 54/F | Middle | Not done | Protruding | Serosa | NS | NS | Surgery | NS |
| 14 (15) | 49/M | Middle | ACC | Protruding | Mucosa | None | None | Surgery | Alive 46 mo. |
| 15 (16) | 47/M | Lower | Not done | Protruding | Mucosa | None | None | Surgery | Alive 3 mo. |
| 16 (17) | 68/F | Lower | Adeno-carcinoma | Ulcerative | NS | NS | NS | Surgery | NS |
| 17 (18) | 60/M | Middle | Not done | Unknown | Muscule | Yes | NS | Surgery | Alive 2 mo. |
| 18 (18) | 58/M | Middle | Not done | Unknown | Sub-adventitia | Yes | NS | Surgery | Alive 37 mo. |
ACC, adenoid cystic carcinoma; DCVU, cisplatin, cyclophosphamide, vomcrostome and uracil; LN, lymph node; M, male; F, female; SCC, squamous cell carcinoma; NS, not stated; mo., month.